Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Tipping the GVH/GVL balance by targeting HIF1α. Cell Rep Med 2023 Nov 21;4(11):101295

Date

11/23/2023

Pubmed ID

37992679

Pubmed Central ID

PMC10694739

DOI

10.1016/j.xcrm.2023.101295

Scopus ID

2-s2.0-85177835310 (requires institutional sign-in at Scopus site)

Abstract

Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.1.

Author List

Wu Y, Yu XZ

Authors

Yongxia Wu PhD Assistant Professor in the Microbiology and Immunology department at Medical College of Wisconsin
Xue-Zhong Yu MD Professor in the Microbiology and Immunology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans